Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | PPIA | P62937 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | BIRC5 | O15392 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884641 | 0.90 | TMPRSS4 (0.40) | TMPRSS4PPIAP2RX1ADRA1DF2 | |
| SCHEMBL21884399 | 0.89 | GAA (0.35) | PPIAF2F10PLGPLAU | |
| SCHEMBL21885702 | 0.89 | PPIA (0.35) | TMPRSS4PPIAP2RX1P2RX7S1PR3 | |
| SCHEMBL21884418 | 0.87 | S1PR3 (0.37) | TMPRSS4CNR2PPIAP2RX1ADRA1D | |
| SCHEMBL21884664 | 0.86 | F2 (0.37) | F2F10PLAUPLATALDH1A1 | |
| SCHEMBL21884460 | 0.86 | BIRC5 (0.40) | TMPRSS4PPIAP2RX1ALDH1A1P2RX4 | |
| SCHEMBL21884581 | 0.86 | KCNMA1 (0.42) | TMPRSS4F10ALDH1A1LMNAS1PR3 | |
| SCHEMBL21884434 | 0.86 | L3MBTL1 (0.38) | PPIAALDH1A1LMNAS1PR3 | |
| SCHEMBL21884447 | 0.84 | CNR2 (0.35) | TMPRSS4CNR2P2RX1ADRA1DP2RX4 | |
| SCHEMBL21884519 | 0.84 | PIK3CA (0.36) | TMPRSS4P2RX1ALDH1A1LMNAS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | TMPRSS4 1380/4885CNR2 2493/4885PPIA 1961/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | TMPRSS4 3136/4885CNR2 4620/4885PPIA 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.